Education
About Us
Working with TipRanks
Follow Us
AstraZeneca PLC (GB:AZN)
LSE:AZN
AZN Stock Chart & Stats
Day’s Range― - ―
52-Week Range9,573.51p - 13,388.00p
Previous CloseN/A
Volume91.53K
Average Volume (3M)2.49M
Market Cap
£156.99B
Enterprise Value183.25B
Total Cash (Recent Filing)$5.49B
Total Debt (Recent Filing)$30.11B
Price to Earnings (P/E)28.5
Beta1.03
Next Earnings
Apr 29, 2025EPS Estimate
168.11Last Dividend Ex-Date
Feb 20, 2025Dividend Yield2.42%
Share Statistics
EPS (TTM)3.56
Shares Outstanding1,550,623,500
10 Day Avg. Volume3,451,151
30 Day Avg. Volume2,489,490
Financial Highlights & Ratios
PEG Ratio1.90
Price to Book (P/B)N/A
Price to Sales (P/S)4.31
Price to Cash Flow (P/CF)18.50
P/FCF Ratio25.00
Enterprise Value/Market Cap1.17
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.18
Enterprise Value/Ebitda10.64
Forecast
1Y Price Target
13,501.38pPrice Target Upside33.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
---
Bulls Say, Bears Say
Bulls Say
Commercial OpportunitiesSees large commercial opportunity for Baxdrostat in monotherapy hypertension setting, with resistant hypertension likely 5-20% of total hypertension population.
Drug EfficacyAZN bullish on Camizestrant SERENA-6 headline data with excitement about its efficacy profile and confidence in safety.
Bears Say
Profit MarginMargin 33.2% (-80bps YoY), mainly on worse GM, with AZN guide indicating FY25 GM decline c60-70bps YoY on IRA, VBP China and growth of royalty products.
Valuation ConcernsValuation (c13x 26E P/E) looks attractive, but mid-term guide implies high-single digit sales CAGR & supports rerating to 18x 26E P/E.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.03% Insiders
13.10%
Mutual Funds
0.01% Other Institutional Investors
77.56% Public Companies and
Individual Investors
AZN FAQ
What was AstraZeneca PLC’s price range in the past 12 months?
AstraZeneca PLC lowest share price was 9573.50p and its highest was 13388.00p in the past 12 months.
What is AstraZeneca PLC’s market cap?
AstraZeneca PLC’s market cap is £156.99B.
When is AstraZeneca PLC’s upcoming earnings report date?
AstraZeneca PLC’s upcoming earnings report date is Apr 29, 2025 which is in 9 days.
How were AstraZeneca PLC’s earnings last quarter?
AstraZeneca PLC released its earnings results on Feb 06, 2025. The company reported 1.582p earnings per share for the quarter, beating the consensus estimate of 1.566p by 0.015p.
Is AstraZeneca PLC overvalued?
According to Wall Street analysts AstraZeneca PLC’s price is currently Undervalued.
Does AstraZeneca PLC pay dividends?
AstraZeneca PLC pays a Annually dividend of 167.999p which represents an annual dividend yield of 2.42%. See more information on AstraZeneca PLC dividends here
What is AstraZeneca PLC’s EPS estimate?
AstraZeneca PLC’s EPS estimate is 168.11.
How many shares outstanding does AstraZeneca PLC have?
AstraZeneca PLC has 1,550,623,500 shares outstanding.
What happened to AstraZeneca PLC’s price movement after its last earnings report?
AstraZeneca PLC reported an EPS of 1.582p in its last earnings report, beating expectations of 1.566p. Following the earnings report the stock price went up 5.932%.
Which hedge fund is a major shareholder of AstraZeneca PLC?
Currently, no hedge funds are holding shares in GB:AZN
---
AstraZeneca Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
13,501.38p (33.36% Upside)
13,501.38p (33.36% Upside)
Insider Transactions
Bought Shares
Worth £151.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.85%
12-Months-Change
Fundamentals
Return on Equity
17.43%
Trailing 12-Months
Asset Growth
4.72%
Trailing 12-Months
Company Description
AstraZeneca PLC
AstraZeneca (AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company operates primarily in three main therapy areas: Oncology, Cardiovascular, Renal & Metabolism (CVRM), and Respiratory & Immunology. AstraZeneca is committed to advancing innovative solutions for patients and healthcare systems worldwide, leveraging its extensive research and development capabilities.
---
AZN Stock 12 Month Forecast
Average Price Target
13,501.38p
▲(33.36% Upside)
Technical Analysis
Best Analysts Covering AZN
1 Year
1 Year Success Rate
26/31 ratings generated profit
1 Year Average Return
+13.57%
reiterated a buy rating 10 days ago
Copying Matthew Weston's trades and holding each position for 1 Year would result in 83.87% of your transactions generating a profit, with an average return of +13.57% per trade.
---